OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
2.657
-0.253 (-8.69%)
At close: Oct 29, 2024, 4:00 PM
2.590
-0.067 (-2.52%)
After-hours: Oct 29, 2024, 7:53 PM EDT
OS Therapies Employees
As of December 31, 2022, OS Therapies had 4 total employees, including 3 full-time and 1 part-time employees.
Employees
4
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,637,445
Market Cap
55.49M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Mural Oncology | 117 |
| Precision BioSciences | 109 |
| InspireMD | 66 |
| Kronos Bio | 63 |
| Aerovate Therapeutics | 51 |
| enVVeno Medical | 31 |
| Milestone Scientific | 17 |
| MAIA Biotechnology | 13 |
OSTX News
- 1 day ago - OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors - Business Wire
- 5 days ago - OS Therapies to Present at the LD Micro Main Event XVII - Business Wire
- 12 days ago - OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - Business Wire
- 26 days ago - OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit - Business Wire
- 6 weeks ago - OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates - Business Wire
- 6 weeks ago - OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models - Accesswire
- 7 weeks ago - OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference - Business Wire
- 2 months ago - OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose - Business Wire